Lexicon Pharmaceuticals, Inc. - LXRX STOCK NEWS

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the acceptance of data from its Phase 2 trial, RELIEF-PHN-1, for investigational drug LX9211 in treating postherpetic neuralgia (PHN) at the AAN Annual Meeting in Boston.

The trial results will be presented on April 24, 2023. Previous data from December 2022 indicated LX9211's potential as an effective non-opioid treatment for neuropathic pain, following positive results from another trial, RELIEF-DPN-1, demonstrating significant pain reduction.

LX9211 targets neuropathic pain via AAK1 inhibition and has Fast Track designation from the FDA for diabetic peripheral neuropathic pain. Overall, the company aims to develop innovative medicines to transform patient care.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. Key executives, including CEO Lonnel Coats, CFO Jeffrey L. Wade, and CMO Craig Granowitz, will engage in a moderated discussion on April 19th at 10:15 AM ET.

The event will be streamed live, and the recording will be accessible for two weeks post-event on the company’s website. Lexicon is focused on developing innovative medicines through its Genome5000™ program, which has identified over 100 protein targets for various diseases.

With a commitment to transforming lives, Lexicon has one marketed medicine and is actively developing candidates for conditions like heart failure and diabetes.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced new analyses from the SOLOIST-WHF Phase 3 study of sotagliflozin, revealing a statistically significant reduction in risk for cardiovascular events by Day 27 for patients with worsening heart failure. This analysis demonstrated the first day post-randomization where the hazard ratio for the primary outcome was significant (p<0.05). The study included 1,222 patients with type 2 diabetes recently hospitalized for worsening heart failure and showed a 33% reduction in composite cardiovascular outcomes.

Lexicon Pharmaceuticals has launched a new disease awareness campaign named “INTO THE DARK” to address the critical period following heart failure (HF) hospitalization. Focusing on the first 30 days post-discharge, the campaign highlights that nearly 25% of HF patients are readmitted within this timeframe, facing a 7% mortality rate. Each rehospitalization costs the healthcare system about $15,000-26,000. The initiative was unveiled at the American College of Cardiology’s 72nd Annual Scientific Session in New Orleans, emphasizing the urgent need for increased awareness and education among healthcare professionals to reduce rehospitalizations.

Lexicon Pharmaceuticals (NASDAQ: LXRX) is set for a May 2023 PDUFA date for their NDA for sotagliflozin in heart failure treatment, confirmed during a recent FDA meeting. The company highlighted positive outcomes from their SOLOIST-WHF trial, showing a 50% reduction in readmission rates for heart failure post-discharge. For LX9211, the Phase 2 studies in diabetic peripheral neuropathic pain and postherpetic neuralgia showed promising results, though the latter's primary endpoint wasn't statistically significant. Financially, Q4 2022 recorded a net loss of $30.5 million but has $138.4 million in cash, a notable increase from $86.7 million in Q4 2021.

Lexicon Pharmaceuticals (Nasdaq: LXRX) is set to release its fourth quarter financial results on March 2, 2023, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results and provide a business update. Lexicon is known for its innovative medicines aimed at transforming patient lives through its Genome5000™ program, having identified over 100 therapeutic protein targets. They have advanced one drug to market and continue to develop candidates in areas such as neuropathic pain and diabetes. The company acknowledges potential risks related to capital requirements and regulatory approvals for its drug candidates.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the upcoming presentation of new analyses from the SOLOIST-WHF Phase 3 study of sotagliflozin at the American College of Cardiology’s 72nd Annual Scientific Session on March 4-6, 2023, in New Orleans. The presentations will include topics such as the time to clinical benefit and effects on symptoms and quality of life in patients with worsening heart failure. The SOLOIST-WHF study, involving 1,222 patients with type 2 diabetes, evaluated the cardiovascular efficacy of sotagliflozin compared to placebo and achieved its primary endpoint, demonstrating overall tolerability similar to placebo, as previously published in The New England Journal of Medicine.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will participate in the 41st Annual JP Morgan Healthcare Conference from January 9-12, 2023. CEO Lonnel Coats will present on January 12, with an on-demand availability starting at 3:00 PM ET/12:00 PM PST. The presentation can be accessed via the Events section on Lexicon's website, and a recording will be available for two weeks after the event. Lexicon focuses on developing innovative medicines through its Genome5000™ program, targeting significant therapeutic proteins.

Lexicon Pharmaceuticals announced topline results from the RELIEF-PHN-1 Phase 2 study of LX9211 for postherpetic neuralgia, demonstrating a reduction of 2.42 in average daily pain score (ADPS) at week 6 compared to a 1.62 reduction in the placebo group. Though not statistically significant at the primary endpoint (p=0.12), a consistent effect was noted across the dosing period (p=0.03). The adverse event profile was similar to prior studies, with dizziness being the most common issue. A full analysis will be shared at a medical conference.